Akero Therapeutics announces initiation of Phase 3 SYNCHRONY outcomes trial

Akero Therapeutics announced initiation of the SYNCHRONY Outcomes study, a Phase 3 trial evaluating the efficacy and safety of efruxifermin in patients with compensated cirrhosis, fibrosis stage 4 due to metabolic dysfunction-associated steatohepatitis. “Patients with compensated cirrhosis represent the greatest unmet need among MASH patients due to increased risk of progression to liver failure, hepatocellular carcinoma or death,” said Kitty Yale, chief development officer of Akero. “Based on the encouraging week 36 results of our Phase 2b SYMMETRY study in patients with compensated cirrhosis due to MASH, we believe EFX has the potential to be among the first investigational drugs to be approved for treatment of both pre-cirrhotic and cirrhotic patients.”